Dr Reddy’s Zytorvi Approval: Bold Esophageal Cancer Win
Dr Reddy’s Zytorvi approval in India: toripalimab with chemotherapy for advanced esophageal cancer, 17.7 vs 12.9 months survival in JUPITER-06.
Dr Reddy’s Zytorvi approval in India: toripalimab with chemotherapy for advanced esophageal cancer, 17.7 vs 12.9 months survival in JUPITER-06.